Recombinant BNP on Heart and Renal Function in Acute Heart Failure

Effect of Recombinant BNP on Heart and Renal Function in Acute Decompensated Heart Failure Patients With Acute Renal Injury

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01625403

Enrollment

100

Registered

2012-06-21

Start date

2012-07-31

Completion date

2013-12-31

Last updated

2012-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure, Acute Renal Failure

Keywords

Recombinant BNP, Diuretics, Acute decompensated heart failure, Acute renal injury, Heart function, Renal function

Brief summary

The purpose of this study is to evaluate the efficacy and safety of recombinant human B-type natriuretic peptide (rhBNP) on heart and renal function in patients with acute decompensated heart failure (ADHF) and acute renal injury (AKI).

Detailed description

Patients with acute decompensated heart failure (ADHF) and acute renal injury (AKI) will be randomized to receive standard of care with or without additional rhBNP. Clinical heart function, LVEF, SCr, GFR and other laboratory parameters will be evaluated.

Interventions

DRUGrhBNP

intravenous administration of rhBNP 0.01 µg/kg/min

DRUGstandard of care

standard of care for heart failure

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* acute heart failure with acute renal injury

Exclusion criteria

* not tolerate to rhBNP

Design outcomes

Primary

Measure	Time frame
left ventricular systolic function	90 days

Secondary

Measure	Time frame
serum creatinine	90 days

Countries

China

Contacts

Primary ContactFang Yuan

yuanfangysh@126.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026